


Nidufexor

05/20

ALTERNATE NAMES: LMB 763; 4-[[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl]benzoic acid; 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid; Benzoic acid, 4-(((8-chloro-1,4-dihydro-1-methyl(1)benzopyrano(4,3-C)pyrazol-3-yl)carbonyl)(phenylmethyl)amino)methyl)-

CATALOG #: B3029-1 1 mg
B3029-5 5 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₇H₂₂ClN₃O₄

MOLECULAR WEIGHT: 487.93

CAS NUMBER: 1773489-72-7

APPEARANCE: White Solid

PURITY: ≥98%

SOLUBILITY: ~83 mg/ml in DMSO (may need ultrasonication)

DESCRIPTION: Nidufexor is an agonist of Farnesoid X receptor (FXR). Administration of Nidufexor (10 and 30 mg/kg for 3 weeks) modulates FXR-dependent genes *in vivo* leading to the reduction of steatosis, inflammation, and fibrosis in a murine NASH model. It is in clinical trials in patients with nonalcoholic steatohepatitis (NASH) and diabetic nephropathy.

STORAGE TEMPERATURE: -20°C. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCE: Chianelli, D., Rucker, P.V., Roland, J., et al. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. *J. Med. Chem.* 63(8):3868-3880 (2020).

RELATED PRODUCTS:

Ipragliflozin (Cat. No. B1926)
 Atorvastatin (Cat. No. 2278)
 Mevastatin (Cat. No. 1694)
 Simvastatin (Cat. No. 1693)
 Licogliflozin (Cat. No. B3028)

DISCLAIMER: **FOR RESEARCH USE ONLY! Not to be used on humans.**